Cytokinetics(US:CYTK) Globenewswire·2025-11-12 22:40Core Viewpoint - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company regarding the New Drug Application for aficamten [1][5]. Group 1: Class Action Details - The class action pertains to common stock purchases of Cytokinetics between December 27, 2023, and May 6, 2025, with a lead plaintiff deadline set for November 17, 2025 [1][5]. - Investors who purchased stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable ranking by ISS Securities Class Action Services [4]. Group 3: Case Allegations - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. - The company failed to disclose material risks related to the submission of a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process, leading to investor damages when the truth was revealed [5].